Saratov JOURNAL of Medical and Scientific Research

Results of treatment of optic neuritis

Year: 2018, volume 14 Issue: №4 Pages: 875-879
Heading: Ophtalmology Article type: Original article
Authors: Latypova Е.А.
Organization: Bashkir State Medical University of the Russian Health Care
Summary:

Purpose: to investigate the epidemiological and clinical features of optic neuritis, evaluate the effectiveness of treatment and underlying diseases. Material and Methods. 58 patients (60 eyes) with optic neuritis (ON) were observed. Among them, 54 adults (26 men, 28 women) aged 19-67 years (mean age 36±11.8 years) and 4 children (1 boy, 3 girls) 14-16 years. Along with the standard ophthalmologic examination, electrophysiological studies, visual evoked potentials and magnetic resonance imaging of the brain and orbit, and a consultation with a neurologist were conducted. The patients were divided into two groups. In the main group of 32 patients (34 eyes), the complex treatment is carried out according to the developed method, which includes daily administration of 1 % nicotinic acid solution in the age dose (from 1 ml to 6 ml per day) with pentoxifylline on the background of basic ON therapy. In the control group of 26 patients (26 eyes), along with basic therapy of 1% nicotinic acid, 1 ml intramuscularly is prescribed a course of 10-15 days. Results. The number of children of young working age (65.5%), including children (6.9%). In the overwhelming number of cases, intrabulbar neuritis was diagnosed (84.5%). In 8 of 9 patients, the precursor of retrobulbar neuritis (PN) was multiple sclerosis (MS). Among other etiological causes of ON viral infection prevailed (37.9%). In patients prolonged by the proposed method, an improvement in visual functions (increased visual acuity, expansion of the general boundaries of the visual field) was achieved in 91% of cases, including high vision (0.5-1.0) in 65% of cases; in patients of the control group, these indicators correspond to 54% and 23%. Conclusion. The use of nicotinic acid intravenously in age dosage with pentoxifyllone in complexes with basic therapy allows the use of methods of treatment of optical neuritis using etiology and can be recommended for widespread use in practical ophthalmology.

Bibliography:
1 Egorov VV, Povalyaeva DA, Smolyakova GP, et al. New features to increase the efficiency of pathogenetic treatment of optic neuritis. RMJ Clinical ophthalmology 2016; (3): 140-4
2 Kovtun OP, Korotkikh SA, lonkina IV. Evaluating the effectiveness of neurotrophic therapy partial atrophy of theoptic nerve in patients with multiple sclerosis according to the electrophysiological methods of investigation. Klinicheskaya oftalmologiya 2010; 11 (4): 139-42
3 Sheremet NL, Ronzina IA, Smirnova TV, et al. Optic neuritis and ischemic optic neuropathy: differential diagnosis. Vestnik oftalmologii 2012; (5): 6-10
4 Wang IH. Clinical prospective study of visual function in patients with acute optic neuritis. J Formos Med Assoc 2013; 112 (2): 87-92
5 Latypova EA, Marvanova ZR. A method for treating optic neuritis: patent (RF), №2414900; 2009
6 Gabdrakhmanova AF, Zagidullina ASh, Abizgildina GSh. Partial atrophy of the optic nerve. Ufa: BGMU, 2014; 159 p.
7 Shmidt ТЕ. Differential diagnosis of optic neuritis (review). Zhurnal nevrologii i psikhiatrii 2012; 112 (9): 5-9
8 Skoromets АА, Akhmetsafin AN, Barantsevich ER, et al. Treatment of lumbar spondylogenous neurological syndromes. Saint Petersburg: Gippokrat, 2001; 56 p.
9 Chuchalin AG., Yasnetsov VV. Federal guidelines for the use of medicines (formula system). 17th ed. M.: Vidoks, 2016; 1045 p.
10 Reference Vidal: Medications in Russia. Moscow: AstraFarmServis, 2009; 1760 p.
11 Morozov VI, Yakovlev АА. Diseases of the visual pathway: Clinic. Diagnostics. Treatment. M.: Binom, 2010; 680 p.
12 Kiseleva TN, Polunin GS, Lagutina YuM. Modern aspects of drug correction of circulatory disorders in the vessels of the eye. Vestnik oftalmologii 2007; (2): 37-9
13 Latypova EA. Effectiveness of nicotinic acid and pentoxifylline in a complex treatment of optic nerve diseases. Bashkortostan Medical Journal 2016; 11 (1): 33-7.

AttachmentSize
2018_4-2_875-879.pdf426.1 KB

No votes yet